Table 6KQ1—Baseline characteristics

Clinical His tory (%)
Study, yearGroupAve Age (SD)Male (%)Ave LVEF % (SD)CADMICABGPCI-PTCAStable AnginaUns table AnginaStroke or TIAPVDDMHTNRILVHSBP mmHg (SD)DBP mmHg (SD)BMI (kg/m2)TC (mg/dL)LDL (mg/dL)HDL (mg/dL)TG (mg/dL)Glucose (mg/dL)Serum Creatinine (mg/dL)Serum Potassium (mEq/L)
HOPE, 200038Ramipril 10mg/d
Placebo
66 (7)
66 (7)
72
74
80
81
52
53
26
26
18
17
55
56
25
26
11
11
42
45
39
38
48
46
8
9
139 (20)
139 (20)
79 (11)
79 (11)
28 (4)
28 (4)
PART-2, 200041Ramipril 5–10mg/d
Placebo
60(8)
61 (8)
82
82
43
41
11
9
20
20
8
9
133 (17)
133 (16)
79 (9)
79 (10)
240 (43)
236 (39)
162 (39)
159 (35)
46 (12)
43 (12)
159 (106)
159 (97)
SCAT, 200042Enalapril 20mg/d
Placebo
60 (10)
62 (9)
89
89
100
100
70
71
11
11
39
32
128 (19)
132 (20)
77 (11)
78 (10)
EUROPA, 200343Perindopril 8mg/d
Placebo
60 (9)
60 (9)
86
85
60
61
65
65
29
29
29
30
3
3
7
7
12
13
27
27
137 (16)
137 (15)
82 (8)
82 (8)
Kondo et al, 200344Candesartan 4mg/d
Control
65 (9)
65 (10)
74
77
63 (10)
62 (10)
67
70
27
23
48
39
129 (13)
128 (14)
76 (8)
76 (8)
24 (2)
23 (2)
187 (28)
187 (31)
114 (25)
112 (30)
49 (12)
49 (14)
126 (73)
127 (77)
118 (32)
117 (38)
CAMELOT, 200445Enalapril 20mg/d
Amlodipine 10mg/d
Placebo
59 (10)
57 (10)
57 (10)
72
76
73
40
37
38
7
8
8
29
26
30
5
4
4
18
17
20
60
61
60
129 (16)
130 (16)
129 (16)
77 (9)
78 (9)
78 (9)
30 (6)
30 (6)
30 (5)
101 (31)
104 (32)
100 (32)
JMIC-B, 200446ACEI
Nifedipine 10–20mg/d
64 (9)
65 (8)
70
68
46
38
21
24
100
100
145 (20)
147 (19)
82 (12)
82 (11)
24 (3)
24 (3)
198 (33)
203 (37)
1.1 (0.4)
1.1 (0.4)
PEACE, 200447Trandolapril 4mg/d
Placebo
64 (8)
64 (8)
81
83
58 (10)
58 (9)
61
61
54
56
38
40
42
41
7
6
18
16
46
45
134 (17)
133 (17)
78 (10)
78 (10)
192 (39)
192 (40)
1.0 (0.2)
1.0 (0.2)
FOSIDIAL, 2006*48Fosinopril 20mg/d
Placebo
67 (8)
67 (8)
54
51
>40%*
>40%*
16
10
100
100
9
6
18
14
35
28
146 (19)
145 (20)
77 (11)
77 (11)
26 (5)
27 (6)
120 (39)
120 (39)
43 (12)
43 (12)
4.9 (0.8)
4.9 (0.8)
Takahashi et al, 200649Candesartan 4–8mg/d
Control
60 (13)
62 (12)
61
57
66 (10)
61 (17)
35
30
84
78
100
100
153 (20)

152 (24)
82 (13)

85 (18)
20 (4)

20 (4)
4.8 (0.9)

4.4 (1.3)
SMILE-ISCHEMIA, 200750Zofenopril 60mg/d
Placebo
58 (10)
58 (10)
81
85
55 (10)
53 (8)
100
100
18
17
45
45
127 (14)
129 (14)
78 (8)
79 (8)
28 (4)
28 (4)
232 (40)
227 (39)
159 (20)
156 (19)
38 (2)
37 (2)
169 (15)
167 (19)
TRANSCEND, 200851Telmisartan 80mg/d
Placebo
67 (7)
67 (7)
57
57
75
74
47
46
19
19
27
26
37
37
16
15
22
22
12
11
36
36
77
76
13
14
141 (17)
141 (16)
82 (10)
82 (10)
28 (5)
28 (5)
197 (46)
196 (45)
117 (39)
117 (39)
49 (14)
50 (16)
159 (116)
157 (97)
117 (44)
117 (44)
1.04 (0.3)
1.04 (0.3)
4.4 (0.4)
4.4 (0.5)
*

The corresponding author for the FOSIDIAL trial reported that all trial participants had normal LVEF, although specific data was not provided

= Patients in the ACEI group were given enalapril 5–10mg/d, imidapril 5–10mg/d, or lisinopril 10–20mg/d

SCAT was a 2X2 factorial design with simvastain 40mg

Abbreviations: ACEI= angiotensin converting enzyme inhibitor; CABG=coronary artery bypass grafting; CAD=coronary artery disease; DM=diabetes mellitus; HTN=hypertension; LVEF=left ventricular ejection fraction; LVH=left ventricular hypertrophy; MI=myocardial infarction; PCI=percutaneous coronary intervention; PTCA=percutaneous transluminal coronary angioplasty; PVD=peripheral vascular disease; RI=renal insufficiency; SD=standard deviation; TIA=transient ischemic attack

Abbreviations: ACEI=angiotensin converting enzyme inhibitor; BMI=body mass index; DBP=diastolic blood pressure; HDL=high-density lipoprotein; LDL=low-density lipoprotein; SBP=systolic blood pressure; SD=standard deviation; TC=total cholesterol; TG=triglycerides

From: Results

Cover of Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease [Internet].
Comparative Effectiveness Reviews, No. 18.
Coleman CI, Baker WL, Kluger J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.